We propose a 4A conceptual frameworkAccessibility, Agility, Awareness, and Adaptability to accelerate therapeutic development and expand access to care for these underserved rare disease populations
I know I have posted this before, but this product works
Dasatinib + FOLFOX + Cetuximab in Clinical Trials for Metastatic Colon Cancer: Early Results and Strategies to Predict Response
Samples (30 g protein) were resolved by 420% SDS-PAGE (Biofuraw Precast Gel, Tanon Science, Shanghai, China), transferred to polyvinylidene difluoride membranes, and incubated with one of the following antibodies: LC3 (88588s, Cell Signaling Technology, 1:1000), GPX4 (ab125066, Abcam, 1:1000), p16 (1003-1-AP, Proteintech, 1:1000)